Zymergen (NASDAQ:ZY – Get a rating) is one of 40 public companies in the “Commercial Physical Research” sector, but how does it compare to its competitors? We will compare Zymergen to related companies based on strength of institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.
Institutional and insider ownership
48.8% of Zymergen shares are held by institutional investors. By comparison, 56.5% of the shares of all “commercial physical research” companies are held by institutional investors. 10.6% of the shares of all “Commercial Physical Research” companies are held by insiders of the company. Strong institutional ownership indicates that endowments, large fund managers, and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares the net margins, return on equity and return on assets of Zymergen and its competitors.
| Net margins | Return on equity | return on assets | |
| Zymergen | -2,160.81% | -213.99% | -64.50% |
| Zymergen competitors | -255.16% | -16.00% | -2.18% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Zymergen and its competitors, as provided by MarketBeat.
| Sales Ratings | Hold odds | Buy reviews | Strong buy odds | Rating | |
| Zymergen | 3 | 5 | 0 | 0 | 1.63 |
| Zymergen competitors | 100 | 744 | 1293 | 30 | 2.58 |
Zymergen currently has a consensus price target of $6.75, indicating a potential upside of 287.93%. As a group, the “Commercial Physical Research” companies have an upside potential of 24.50%. Given Zymergen’s possible higher upside, equity research analysts clearly believe that Zymergen is more favorable than its competitors.
Valuation and benefits
This table compares the gross revenue, earnings per share (EPS), and valuation of Zymergen and its competitors.
| Gross revenue | Net revenue | Price/earnings ratio | |
| Zymergen | $16.74 million | -$361.79 million | -0.18 |
| Zymergen competitors | $2.79 billion | $101.13 million | 22.22 |
Zymergen’s competitors have higher revenues and profits than Zymergen. Zymergen trades at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
Zymergen’s competitors beat Zymergen on 11 of the 12 factors compared.
Zymergen Company Profile (Get a rating)
Zymergen Inc. designs, develops and markets microbes, molecules and materials. It offers an automation solution including reconfigurable automation carts, modular hardware building blocks that enable the assembly of custom work cells for a lab’s particular needs; and automation control software, cloud-based software used to control embedded automation systems. It serves electronics, packaging, healthcare, agriculture and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California.
Get news and reviews for Zymergen Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Zymergen and related companies with MarketBeat.com’s FREE daily email newsletter.
